Q&A: Page 2
Exclusive interviews with industry leaders
-
Permission granted by Portal Bio
SQZ, Portal founder Armon Sharei on starting over in biotech
After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.
Gwendolyn Wu • March 26, 2024 -
Permission granted by Boehringer Ingelheim
Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim
Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”
Alexandra Pecci • March 25, 2024 -
Permission granted by Wyss Institute
An ocean of answers in a single cell — how proteomics can lead to better drugs
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
Michael Gibney • March 21, 2024 -
Stock via Getty Images
GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.
Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.
Alexandra Pecci • March 19, 2024 -
Alex Wong/Getty Images via Getty Images
Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
Michael Gibney • March 14, 2024 -
Permission granted by Tarsus Pharmaceuticals
Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
Meagan Parrish • March 8, 2024 -
iStock via Getty Images
Biogen partner NeuroSense seeks a role in the ALS revolution
Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.
Michael Gibney • Feb. 29, 2024 -
Maddie Meyer via Getty Images
For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test
Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.
Amy Baxter • Feb. 23, 2024 -
Permission granted by Mural Oncology
Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
Alexandra Pecci • Feb. 6, 2024 -
Permission granted by Amylyx
‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
Meagan Parrish • Jan. 26, 2024 -
Permission granted by 4DMT
One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery
4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.
Michael Gibney • Jan. 10, 2024 -
iStock via Getty Images
This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain
Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.
Michael Gibney • Dec. 19, 2023 -
Permission granted by Quita Highsmith
The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them
Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.
Michael Gibney • Dec. 14, 2023 -
Permission granted by FNIH
A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.
Meagan Parrish • Dec. 13, 2023 -
Permission granted by Adam Lenkowsky
Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
Michael Gibney • Dec. 12, 2023 -
Justin Sullivan via Getty Images
Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV
Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.
Alexandra Pecci • Dec. 11, 2023 -
Permission granted by AstraZeneca
The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech
Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.
Michael Gibney • Nov. 28, 2023 -
Permission granted by Organon
Organon’s chief medical officer wants to change how the world sees women’s health
Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.
Michael Gibney • Nov. 22, 2023 -
Permission granted by AstraZeneca/U. of Birmingham
AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?
Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.
Michael Gibney • Nov. 16, 2023 -
Dia Dipasupil via Getty Images
23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’
23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.
Alexandra Pecci • Nov. 7, 2023 -
iStock via Getty Images
Wisp’s ‘bold and unapologetic approach’ to women’s sexual and reproductive health
In the role of interim CEO of Wisp, Monica Cepak aims to break down barriers and expand access via telehealth.
Alexandra Pecci • Oct. 31, 2023 -
Photo illustration: Industry Dive; Getty Images
Red Jacket: Dr. Mark Goldberg, a clinical innovator
Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.
Alexandra Pecci • Oct. 27, 2023 -
Photo illustration: Industry Dive; Getty Images
Red Jacket: Dr. Jeremy Levin, a transformational leader
A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.
Michael Gibney • Oct. 27, 2023 -
Permission granted by Precigen
Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.
Meagan Parrish • Oct. 27, 2023 -
Industry Dive; Getty Images
Red Jacket: Ken Getz, a champion of clinical trials
Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.
Alexandra Pecci • Oct. 27, 2023
Previous
